There are about 240 million chronic hepatitis B virus (HBV) infected people in the world, and about 2%-5% of compensated cirrhosis patients progress to decompensated cirrhosis patients every year. Studies have shown that the 5-year survival rate of decompensated cirrhosis is only 14-35%, and the quality of life and prognosis of patients are poor. Reversing or delaying the process of cirrhosis and reducing the development of compensated cirrhosis to decompensated cirrhosis is one of the effective methods for liver disease treatment. MSCs are mainly derived from bone marrow, but bone marrow mesenchymal stem cells have some shortcomings, such as cumbersome sampling, and the proliferation and differentiation ability of bone marrow mesenchymal stem cells decrease obviously with the age of donors, which is not conducive to cell therapy. Umbilical cord has many advantages, such as wide source, convenient collection, small immune rejection, and small ethical controversy, which makes it a hot spot in stem cell research and has a wider prospect in cell therapy. This clinical study will explore the efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of hepatitis B virus-infected patients with compensated cirrhosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
FibroScan
Timeframe: Change from Baseline Liver stiffness at week 24
IV-C
Timeframe: Change from Baseline at week 24
HA
Timeframe: Change from Baseline at week 24
LN
Timeframe: Change from Baseline at week 24
PC-III
Timeframe: Change from Baseline at week 24
Hepatic histopathologic examination
Timeframe: Change from Baseline at week 24
IgG
Timeframe: Change from Baseline at week 24
IgA
Timeframe: Change from Baseline at week 24
IgM
Timeframe: Change from Baseline at week 24
IgE
Timeframe: Change from Baseline at week 24
C3
Timeframe: Change from Baseline at week 24
C4
Timeframe: Change from Baseline at week 24
CD3
Timeframe: Change from Baseline at week 24
CD4
Timeframe: Change from Baseline at week 24
CD8
Timeframe: Change from Baseline at week 24
CD19
Timeframe: Change from Baseline at week 24
CD16+56
Timeframe: Change from Baseline at week 24